GH Guardant Health, Inc.

145.83USD+0.16%Mkt Cap: 19.73B USDP/E: —

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutati…

Insiders, last 90 daysNet sellers
Institutional holders20 on file

Key Statistics

Company
Market Cap19.73B USD
Enterprise Value20.36B USD
Revenue (TTM)1.28B USD
Gross Profit633.01M USD
Net Income (TTM)-416.28M USD
Revenue/Share9.70 USD
Last Price145.83 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees2.5K
CountryUS
SectorHealthcare
IndustryDiagnostics & Research
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-475.19
PEG—
EV/EBITDA-43.82
EV/Revenue15.92
P/S15.43
P/B-71.21
EPS (TTM)-3.68 USD
EPS (Forward)-0.31 USD
52W Range
74.5561% of range191.01
52W High191.01 USD
52W Low74.55 USD
Profitability
Gross Margin64.46%
Oper. Margin-39.40%
EBITDA Margin-36.34%
Profit Margin-42.39%
ROE419.18%
ROA-20.67%
ROIC-106.52%
ROCE-25.56%
Growth
Revenue Growth36.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-184.76M USD
CapEx (TTM)48.31M USD
FCF Margin-4.73%
FCF Yield-0.31%
Net Debt664.59M USD
Net Debt/EBITDA-1.43
Net Debt/FCF—
Balance Sheet
Debt/Equity-17.22
Current Ratio3.60
Quick Ratio3.25
Book Value/Sh-2.05 USD
Cash/Share7.59 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)200.76 USD
Upside (mean)+37.7%
Target Range105.00 USD – 240.00 USD
105.00+37.7% to mean240.00
# Analysts25
Ownership
Shares Out.135.29M
Float130.57M
Insiders3.95%
Institutions99.72%
Short Interest
Short Ratio5.3d
Short % Float7.26%
Short % Out.6.97%
Shares Short9.43M
Short (prev mo.)11.92M
Technical
SMA 50167.59 (-13.0%)
SMA 200133.24 (+9.5%)
Beta1.66
S&P 52W Chg12.00%
Avg Vol (30d)2.09M
Avg Vol (10d)2.69M
Technical Indicators
RSI (14)36.9
MACD-6.4566
MACD Signal-4.7876
MACD Hist.-1.6690
BB Upper189.24 USD
BB Middle160.80 USD
BB Lower132.35 USD
BB Width35.38%
ATR (14)9.306 USD
Vol Ratio (20d)1.22x

About Guardant Health (NASDAQ: GH)

›

Guardant Health (NASDAQ: GH) is listed on Nasdaq, where its shares trade in USD. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 2,490 employees.

The shares were at 145.83 USD on 20 November 2026, up 50.8% over 52 weeks. Its 52-week range is 74.55 USD to 191.01 USD: the price is 23.7% below the high and 95.6% above the low.

Its market capitalisation is 19.73B USD.

Guardant Health reports return on equity of 419.2%, an operating margin of -39.4% and revenue up 36.1% year over year.

Its debt exceeds its cash by 664.59M USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 25 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 200.76 USD is 37.7% above the current price. The next earnings report is expected on 18 February 2027.